A mixture containing AI-designed bacteriophage variants has been used in humans for the first time to treat patients with drug-resistant bacterial infections, a technological breakthrough that has drawn attention in the field of biosafety. Drug-resistant bacterial infections have become a major global public health challenge, and traditional bacteriophage therapy requires a time-consuming process of screening bacteriophage libraries one by one. Radical Numerics has introduced a multimodal genomic model, Omnii-1, capable of learning various types of biological information, predicting the compatibility between bacteriophages and bacteria, and generating optimized new variants of bacteriophages, thereby significantly improving the efficiency of screening and designing candidate bacteriophages. The company has secured $50 million in seed funding, with its platform business spanning multiple areas including diagnostics, treatment, industrial applications, and biodefense. The bacteriophage design is the first project applied to patient treatment, and will subsequently face challenges such as wet experiments and clinical translation. The establishment of repeatable and standardized clinical processes remains a core issue that the industry urgently needs to address.